Inflammation-associated lymphangiogenesis: A double-edged sword?

Journal of Clinical Investigation

Volumn 124, Issue 3, 2014, Pages 936-942

  Kim, Honsoul ^a   Kataru, Raghu P ^b   Koh, Gou Young ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CELL INTERACTION; DIABETES MELLITUS; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFLAMMATION; INFLAMMATION ASSOCIATED LYMPHANGIOGENESIS; INFLAMMATORY BOWEL DISEASE; LYMPH VESSEL; LYMPHANGIOGENESIS; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SIGNAL TRANSDUCTION;

ANGIOGENIC PROTEINS; ANIMALS; DIABETES MELLITUS; GRAFT REJECTION; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; LYMPHANGIOGENESIS; RESPIRATORY SYSTEM; SIGNAL TRANSDUCTION;

EID: 84896790526     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71607     Document Type: Review

References (90)

1. Mouta C, Heroult M. Inflammatory triggers of lymphangiogenesis. Lymphat Res Biol. 2003; 1(3):201-218.
2. Robbins SL, Kumar V, Cotran RS. Robbins And Cotran Pathologic Basis Of Disease. Philadelphia, Pennsylvania, USA: Saunders/Elsevier; 2010.
3. Alitalo K. The lymphatic vasculature in disease. Nat Med. 2011;17(11):1371-1380.
4. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell. 2010;140(4):460-476.
5. Kim H, Kataru RP, Koh GY. Regulation and implications of inflammatory lymphangiogenesis. Trends Immunol. 2012;33(7):350-356.
6. Avraham T, et al. Fibrosis is a key inhibitor of lymphatic regeneration. Plast Reconstr Surg. 2009;124(2):438-450.
7. Paupert J, Sounni NE, Noel A. Lymphangiogenesis in post-natal tissue remodeling: lymphatic endothelial cell connection with its environment. Mol Aspects Med. 2011;32(2):146-158.
8. Yao LC, Baluk P, Srinivasan RS, Oliver G, McDonald DM. Plasticity of button-like junctions in the endothelium of airway lymphatics in development and inflammation. Am J Pathol. 2012;180(6):2561-2575.
9. Zgraggen S, Ochsenbein AM, Detmar M. An important role of blood and lymphatic vessels in inflammation and allergy. J Allergy (Cairo). 2013;2013:672381.
10. Alvarez D, Vollmann EH, von Andrian UH. Mechanisms and consequences of dendritic cell migration. Immunity. 2008;29(3):325-342.
11. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol. 2005;5(8):617-628.
12. Mumprecht V, Roudnicky F, Detmar M. Inflammation-induced lymph node lymphangiogenesis is reversible. Am J Pathol. 2012;180(3):874-879.
13. Bielenberg DR, D'Amore PA. All vessels are not created equal. Am J Pathol. 2013;182(4):1087-1091.
14. Kastenmuller W, Torabi-Parizi P, Subramanian N, Lammermann T, Germain RN. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. Cell. 2012;150(6):1235-1248.
15. Hirai S, et al. Lymphangiogenesis in chronic inflammation in the testis. Andrology. 2013;1(1):147-154.
16. Maruyama K, et al. Inf lammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005; 115(9):2363-2372.
17. Kerjaschki D, et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med. 2006;12(2):230-234.
18. Lee JY, et al. Podoplanin-expressing cells derived from bone marrow play a crucial role in postnatal lymphatic neovascularization. Circulation. 2010;122(14):1413-1425.
19. Hall KL, Volk-Draper LD, Flister MJ, Ran S. New model of macrophage acquisition of the lymphatic endothelial phenotype. PLoS One. 2012;7(3):e31794.
20. Zumsteg A, Christofori G. Myeloid cells and lymphangiogenesis. Cold Spring Harb Perspect Med. 2012;2(6):a006494.
21. Huggenberger R, et al. An important role of lymphatic vessel activation in limiting acute inflammation. Blood. 2011;117(17):4667-4678.
22. Baluk P, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest. 2005;115(2):247-257.
23. Guo R, et al. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum. 2009; 60(9):2666-2676.
24. Wirzenius M, et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med. 2007; 204(6):1431-1440.
25. Kataru RP, et al. Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood. 2009;113(22):5650-5659.
26. Kunstfeld R, et al. Induction of cutaneous delayedtype hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood. 2004;104(4):1048-1057.
27. Zhu M, Fu YX. The role of core TNF/LIGHT family members in lymph node homeostasis and remodeling. Immunol Rev. 2011;244(1):75-84.
28. Mounzer RH, et al. Lymphotoxin-alpha contributes to lymphangiogenesis. Blood. 2010;116(12):2173-2182.
29. Babu S, Anuradha R, Kumar NP, George PJ, Kumaraswami V, Nutman TB. Toll-like receptor-and filarial antigen-mediated, mitogen-activated protein kinase-and NF-κB-dependent regulation of angiogenic growth factors in filarial lymphatic pathology. Infect Immun. 2012;80(7):2509-2518.
30. Flister MJ, et al. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-κB and Prox1. Blood. 2010;115(2):418-429.
31. Lee AS, et al. Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis. Cancer Res. 2011;71(13):4506-4517.
32. Hosono K, et al. Roles of prostaglandin E2-EP3/ EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation. Arterioscler Thromb Vasc Biol. 2011;31(5):1049-1058.
33. Kashiwagi S, Hosono K, Suzuki T, Takeda A, Uchinuma E, Majima M. Role of COX-2 in lymphangiogenesis and restoration of lymphatic flow in secondary lymphedema. Lab Invest. 2011; 91(9):1314-1325.
34. Kataru RP, et al. T lymphocytes negatively regulate lymph node lymphatic vessel formation. Immunity. 2011;34(1):96-107.
35. Oka M, et al. Inhibition of endogenous TGF-β signaling enhances lymphangiogenesis. Blood. 2008;111(9):4571-4579.
36. Clavin NW, et al. TGF-β1 is a negative regulator of lymphatic regeneration during wound repair. Am J Physiol Heart Circ Physiol. 2008;295(5):H2113-H2127.
37. Avraham T, et al. Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair. Am J Pathol. 2010; 177(6):3202-3214.
38. Ou J, et al. Endostatin suppresses colorectal tumorinduced lymphangiogenesis by inhibiting expression of fibronectin extra domain A and integrin α9. J Cell Biochem. 2011;112(8):2106-2114.
39. Cursiefen C, et al. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med. 2011;208(5):1083- 1092.
40. Zampell JC, et al. Lymphatic function is regulated by a coordinated expression of lymphangiogenic and anti-lymphangiogenic cytokines. Am J Physiol Cell Physiol. 2012;302(2):C392-C404.
41. Angeli V, et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity. 2006;24(2):203-215.
42. Shrestha B, et al. B cell-derived vascular endothelial growth factor A promotes lymphangiogenesis and high endothelial venule expansion in lymph nodes. J Immunol. 2010;184(9):4819-4826.
43. Kim KE, et al. Role of CD11b+ macrophages in intraperitoneal lipopolysaccharide-induced aberrant lymphangiogenesis and lymphatic function in the diaphragm. Am J Pathol. 2009;175(4):1733-1745.
44. Chyou S, et al. Fibroblast-type reticular stromal cells regulate the lymph node vasculature. J Immunol. 2008;181(6):3887-3896.
45. Halin C, Tobler NE, Vigl B, Brown LF, Detmar M. VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood. 2007;110(9):3158-3167.
46. Liao S, Ruddle NH. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J Immunol. 2006;177(5):3369-3379.
47. Mumprecht V, Roudnicky F, Detmar M. Inflammation-induced lymph node lymphangiogenesis is reversible. Am J Pathol. 2011;180(3):874-879.
48. Tan KW, et al. Expansion of cortical and medullary sinuses restrains lymph node hypertrophy during prolonged inflammation. J Immunol. 2012;188(8):4065-4080.
49. Yao LC, Baluk P, Feng J, McDonald DM. Steroid-resistant lymphatic remodeling in chronically inflamed mouse airways. Am J Pathol. 2010;176(3):1525-1541.
50. Kelley PM, Connor AL, Tempero RM. Lymphatic vessel memory stimulated by recurrent inflammation. Am J Pathol. 2013;182(6):2418-2428.
51. Tewalt EF, Cohen JN, Rouhani SJ, Engelhard VH. Lymphatic endothelial cells - key players in regulation of tolerance and immunity. Front Immunol. 2012;3:305.
52. Dietrich T, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol. 2010; 184(2):535-539.
53. Baluk P, et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med. 2007;204(10):2349-2362.
54. Pflicke H, Sixt M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J Exp Med. 2009;206(13):2925-2935.
55. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6(12):1191-1197.
56. Ji RC. Macrophages are important mediators of either tumor-or inflammation-induced lymphangiogenesis. Cell Mol Life Sci. 2012;69(6):897-914.
57. Schoppmann SF, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161(3):947-956.
58. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008;8(5):362-371.
59. Tal O, et al. DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling. J Exp Med. 2011;208(10):2141-2153.
60. Johnson LA, Clasper S, Holt AP, Lalor PF, Baban D, Jackson DG. An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J Exp Med. 2006;203(12):2763-2777.
61. Angeli V, Randolph GJ. Inflammation, lymphatic function, and dendritic cell migration. Lymphat Res Biol. 2006;4(4):217-228.
62. Chen L, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med. 2004;10(8):813-815.
63. Nykanen AI, et al. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. Circulation. 2010;121(12):1413-1422.
64. El-Chemaly S, Pacheco-Rodriguez G, Ikeda Y, Malide D, Moss J. Lymphatics in idiopathic pulmonary fibrosis: new insights into an old disease. Lymphat Res Biol. 2009;7(4):197-203.
65. Marchal-Somme J, et al. Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J Immunol. 2006;176(10):5735-5739.
66. Pierce EM, et al. Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 11. Eur Respir J. 2007;29(6):1082-1093
67. Jurisic G, Sundberg JP, Detmar M. Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement. Inflamm Bowel Dis. 2013;19(9):1983-1989.
68. Ganta VC, et al. Angiopoietin-2 in experimental colitis. Inflamm Bowel Dis. 2010;16(6):1029-1039.
69. Jang JY, et al. Conditional ablation of LYVE-1+ cells unveils defensive roles of lymphatic vessels in intestine and lymph node. Blood. 2013;122(13):2151-2161.
70. Fogt F, Pascha TL, Zhang PJ, Gausas RE, Rahemtulla A, Zimmerman RL. Proliferation of D2-40-expressing intestinal lymphatic vessels in the lamina propria in inflammatory bowel disease. Int J Mol Med. 2004;13(2):211-214.
71. Heatley RV, Bolton PM, Hughes LE, Owen EW. Mesenteric lymphatic obstruction in Crohn's disease. Digestion. 1980;20(5):307-313.
72. von der Weid PY, Rehal S, Ferraz JG. Role of the lymphatic system in the pathogenesis of Crohn's disease. Curr Opin Gastroenterol. 2011;27(4):335-341.
73. Sura R, Colombel JF, Van Kruiningen HJ. Lymphatics, tertiary lymphoid organs and the granulomas of Crohn's disease: an immunohistochemical study. Aliment Pharmacol Ther. 2011;33(8):930-939.
74. Pedica F, Ligorio C, Tonelli P, Bartolini S, Baccarini P. Lymphangiogenesis in Crohn's disease: an immunohistochemical study using monoclonal antibody D2-40. Virchows Arch. 2008;452(1):57-63.
75. Geleff S, Schoppmann SF, Oberhuber G. Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease. Virchows Arch. 2003;442(3):231-237.
76. Rahier JF, et al. Decreased lymphatic vessel density is associated with postoperative endoscopic recurrence in Crohn's disease. Inflamm Bowel Dis. 2013;19(10):2084-2090.
77. Alexander JS, Chaitanya GV, Grisham MB, Boktor M. Emerging roles of lymphatics in inflammatory bowel disease. Ann N Y Acad Sci. 2010; 1207(suppl 1):E75-E85.
78. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011; 11(2):98-107.
79. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116(7):1793-1801.
80. Yin N, et al. Lymphangiogenesis is required for pancreatic islet inflammation and diabetes. PLoS One. 2011;6(11):e28023.
81. Moriguchi P, Sannomiya P, Lara PF, Oliveira-Filho RM, Greco KV, Sudo-Hayashi LS. Lymphatic system changes in diabetes mellitus: role of insulin and hyperglycemia. Diabetes Metab Res Rev. 2005;21(2):150-157.
82. Haemmerle M, et al. Enhanced lymph vessel density, remodelling and inflammation is reflected by gene expression signatures in dermal lymphatic endothelial cells in type 2 diabetes. Diabetes. 2013;62(7):2509-2529.
83. Yin N, Zhang N, Xu J, Shi Q, Ding Y, Bromberg JS. Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival. Transplantation. 2011;92(1):25-30.
84. Cursiefen C, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45(8):2666-2673.
85. Nakao S, Hafezi-Moghadam A, Ishibashi T. Lymphatics and lymphangiogenesis in the eye. J Ophthalmol. 2012;2012:783163.
86. Bock F, et al. Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res. 2013;34:89-124.
87. Oh JY, Ko JH, Lee HJ, Kim MK, Lee JH, Wee WR. The antigenicity of ex vivo cultivated human corneal limbal epithelial and stromal cells: temporal changes in vitro. Cornea. 2010;29(11):1302-1307.
88. Zakaria N, Van Marck V, Koppen C, Berneman Z, Tassignon MJ. Lymphangiogenesis may play a role in cultivated limbal stem cell transplant rejection. Ocul Immunol Inflamm. 2012;20(5):381-383.
89. Cursiefen C, Maruyama K, Jackson DG, Streilein JW, Kruse FE. Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea. 2006;25(4):443-447.
90. Kerjaschki D, et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol. 2004;15(3):603-612.